Stocks · Healthcare · Biotechnology
ImmuCell Corporation ICCC
$9.75 +1.56% Close, Oct 2, 2026 · NASDAQ · Market cap $88.2M
High qualityInexpensive vs sectorLow risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.08, down 54.8% year over year.
- The stock is in an uptrend: above its 200-day average for 135 trading days, with the 50-day average above the 200-day.
- Operating margin widened to 12.6% from 6.1% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 49%
- EPS growth (TTM, YoY)Bottom 28%
- FCF growth (TTM, YoY)Top 12%
- Revenue growth, 3-year CAGRTop 42%
- Revenue growth accelerationBottom 40%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 19%
- Gross marginBottom 26%
- Operating marginTop 21%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 31%
- Net debt / EBITDA (lower is better)Top 47%
- Interest coverTop 16%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 27%
- Free-cash-flow yieldTop 18%
- EBITDA / enterprise valueTop 28%
- Sales / enterprise valueTop 39%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 33%
- 6-month returnTop 19%
- 1-year return vs S&P 500Top 28%
- Distance from 52-week highTop 31%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsTop 35%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 18%
- Maximum drawdown, 3 yearsTop 13%
- Beta vs S&P 500 (lower is better)Top 3%
- Net debt / EBITDA (lower is better)Top 47%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 9.6% | 8.5% | ↓ |
| Gross margin | 37.4% | 40.3% | ↑ |
| Operating margin | 6.1% | 12.6% | ↑ |
| FCF margin | 6.2% | 13.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 8.5% | 9.6% | ↓ | Bottom 49% |
| EPS growth (TTM, YoY) | -54.8% | — | Bottom 28% | |
| Gross margin | 40.3% | 37.4% | ↑ | Bottom 26% |
| Operating margin | 12.6% | 6.1% | ↑ | Top 21% |
| Net margin | 2.6% | 6.2% | ↓ | — |
| Free-cash-flow margin | 13.7% | 6.2% | ↑ | — |
| Return on invested capital | 8.1% | — | Top 19% | |
| Revenue growth, 3-year CAGR | 14.2% | — | Top 42% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -10.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +11.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.01×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 8.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.19%
- Shareholder yield
- -0.19%
- Share count change, 1 year
- +1.7%
- Share count change, 3-year CAGR
- +5.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 2 of 3
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -0.3%
- Positive 20 days after report
- 3 of 8
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +300.0% | -0.7% | -7.7% | -9.7% | — |
| May 14, 2026 | +320.0% | -1.2% | +18.2% | +16.5% | +31.2% |
| Mar 4, 2026 | -3000.0% | +0.9% | +3.6% | -1.1% | +54.7% |
| Nov 13, 2025 | — | -1.3% | -22.7% | -1.0% | +8.2% |
| Aug 14, 2025 | — | +2.9% | -7.5% | -6.1% | -3.4% |
| May 14, 2025 | — | -1.2% | +11.5% | +26.6% | +34.0% |
| Feb 25, 2025 | — | +1.6% | +2.8% | -1.6% | +10.4% |
| Nov 13, 2024 | — | -3.3% | -1.4% | +23.8% | +38.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | $0.20 | $0.05 | +300.0% | $7.2M |
| May 14, 2026 | $0.21 | $0.05 | +320.0% | $10.4M |
| Mar 4, 2026 | -$0.31 | -$0.01 | -3000.0% | $7.6M |
| Nov 13, 2025 | -$0.02 | — | — | $5.5M |
| Aug 14, 2025 | $0.06 | — | — | $6.4M |
| May 14, 2025 | $0.16 | — | — | $8.1M |
| Feb 25, 2025 | $0.06 | — | — | $7.8M |
| Nov 13, 2024 | -$0.09 | — | — | $6.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 115.2× | — | — | Top 27% |
| EV / EBITDA | 26.0× | — | — | Top 28% |
| EV / Sales | 2.99× | — | — | Top 39% |
| Free-cash-flow yield | 4.78% | — | — | Top 18% |
| Earnings yield | 0.87% | — | — | Top 27% |
P/E over the past five years
Range 23.5× – 244.4× since Mar 31, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +47.7%
- Earnings per share growth (TTM)
- -54.8%
- Change in P/E multiple
- +138.0%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 135
- 50-day average slope (20 days)
- -3.3%
- 200-day average slope (20 days)
- +5.9%
- Distance from 50-day average
- -4.7%
- Distance from 200-day average
- +15.3%
- RSI (14)
- 43.4
- Relative volume
- 0.41×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 37.0%
- Volatility vs own 5-year history
- 5th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.03
- Correlation with S&P 500
- 0.01
- Current drawdown from 1-year high
- -16.8%
- Maximum drawdown, 3 years
- -40.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 19, 2021 | Sep 24, 2024 | -70.3% | 903 days | Not yet recovered |
| Oct 13, 2020 | Oct 28, 2020 | -14.2% | 11 days | 22 days (Nov 30, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $88.2M
- P/E (TTM)
- 115.2
- EPS, diluted (TTM)
- $0.08
- Revenue (TTM)
- $30.7M
- 52-week range
- $4.52 – $12.10
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M |
| Gross profit | $8.7M | $7.6M | $4.4M | $7.9M | $11.4M |
| Operating income | $257,385 | -$2.3M | -$5.7M | -$1.6M | $1.6M |
| Net income | -$78,292 | -$2.5M | -$5.8M | -$2.2M | -$1.0M |
| EPS (diluted) | -$0.01 | -$0.32 | -$0.75 | -$0.26 | -$0.12 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M | $7.6M | $10.4M | $7.2M |
| Net income | -$701,690 | $514,555 | $1.4M | $501,880 | -$139,748 | -$2.8M | $1.9M | $1.8M |
| EPS (diluted) | -$0.09 | $0.06 | $0.16 | $0.06 | -$0.02 | -$0.31 | $0.21 | $0.20 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $954,170 | -$1.5M | -$4.7M | $357,903 | $2.5M |
| Capital expenditure | -$2.6M | -$4.0M | -$1.9M | -$465,725 | -$1.3M |
| Free cash flow | -$1.7M | -$5.5M | -$6.6M | -$107,822 | $1.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $4.2M | $30,670 | $18,760 | $4.4M | $349,329 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $8.9M
- Total assets
- $46.6M
- Total liabilities
- $15.3M
- Total debt
- $12.4M
- Net debt
- $3.6M
- Shareholders’ equity
- $31.4M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 19,828
- Days to cover
- 1.56
- Change vs previous report
- +2.9%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 25, 1990
- 1-for-100